What You Should Know:
– Ro, the healthcare technology company, today announced it has raised $500 million in a Series D fundraising round led by existing investors General Catalyst, FirstMark Capital, and TQ Ventures, with significant participation from existing investors SignalFire, Torch, and BoxGroup as well as new investors Altimeter, Baupost, Dragoneer, Shawspring, Radcliff, and 776. The Series D brings Ro’s total fundraising since its founding in 2017 to $876 million.
– This news follows Ro’s announcement of a first-of-its-kind in-home vaccination program — tapping into each part of our vertically integrated platform — as well as the acquisition of Workpath, which power Ro’s and other companies’ in-home care capabilities.
– Ro plans to use the latest round of capital to strengthen its vertically integrated primary care platform. In addition, Ro plans to expand its pharmacy distribution network, continue to enhance its proprietary EMR (the Ro Collaborative Care Center), build new capabilities such as remote patient monitoring with integrated devices, and broaden into additional treatment areas that leverage its diagnostic capabilities.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
– Ro recently partnered with healthcare AI company Gauss to offer Gauss’s smartphone-powered, at-home COVID-19 rapid antigen tests on its platform upon Food and Drug Administration Emergency Use Authorization.
Source: Hitconsultant
